Platinum agents and mitomycin C-specific complications in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

References

• Kuijpers AM, Mirck B, Aalbers AG, et al. (2013). Cytoreduction and HIPEC in The Netherlands: nationwide long-term outcome following the dutch protocol. Ann Surg Oncol 20:4224–30.
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Halkia E, Lianos E, et al. (2015). Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22:1570–5.
   PubMed Web of Science ®Google Scholar
• Ansari N, Chandrakumaran K, Dayal S, et al. (2016). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol 42:1035–41.
   PubMed Web of Science ®Google Scholar
• Yan TD, Deraco M, Baratti D, et al. (2009). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–42.
   PubMed Web of Science ®Google Scholar
• Chia CS, Tan GHC, Lim C, et al. (2016). Prospective quality of life study for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 23:2905–13.
   PubMed Web of Science ®Google Scholar
• Murphy EM, Sexton R, Moran BJ. (2007). Early results of surgery in 123 patients with Pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum 50:37–42.
   PubMed Web of Science ®Google Scholar
• Elias D, Honoré C, Ciuchendéa R, et al. (2008). Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg 95:1164–71.
   PubMed Web of Science ®Google Scholar
• Mohamed F, Moran BJ. (2009). Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve. Cancer J 15:196–9.
   PubMed Web of Science ®Google Scholar
• Simkens GA, van Oudheusden TR, Luyer MD, et al. (2015). Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis. Ann Surg Oncol 22:2656–62.
   PubMed Web of Science ®Google Scholar
• Newton AD, Bartlett EK, Karakousis GC, et al. (2016). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. J Gastrointest Oncol 7:99–111.
   PubMed Web of Science ®Google Scholar
• Chua TC, Yan TD, Saxena A, Morris DL. (2009). Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 249:900–7.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. (2007). Peritonectomy procedures. Cancer Treat Res 134:247–64.
   PubMedGoogle Scholar
• Witkamp AJ, de Bree E, Van Goethem R, Zoetmulder FA. (2001). Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 27:365–74.
   PubMed Web of Science ®Google Scholar
• Jacquet P, Sugarbaker PH. (1996). Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–74.
   PubMedGoogle Scholar
• Kusamura S, Baratti D, Younan R, et al. (2007). Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol 14:2550–8.
   PubMed Web of Science ®Google Scholar
• Kemmel V, Mercoli H-A, Meyer N, et al. (2015). Mitomycin C pharmacokinetics as predictor of severe neutropenia in hyperthermic intraperitoneal therapy. Ann Surg Oncol 22:873–9.
   Web of Science ®Google Scholar
• Van der Speeten K, Stuart OA, Chang D, et al. (2011). Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 68:147–56.
   PubMed Web of Science ®Google Scholar
• Teo MCC, Tan GHC, Tham CK, et al. (2013). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution. Ann Surg Oncol 20:2968–74.
   PubMed Web of Science ®Google Scholar
• DCTD, NCI, NIH, DHHS. (2006). Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0.
   Google Scholar
• Dindo D, Demartines N, Clavien P-A. (2004). Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–13.
   PubMed Web of Science ®Google Scholar
• R Core Team (2016). R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available from: http://www.R-project.org/.
   Google Scholar
• Charrier G, Passot J, Peron, et al. (2016). Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. Ann Surg Oncol 2:2315–22.
   Web of Science ®Google Scholar
• Hakeam AH, Breakiet M, Azzam A, et al. (2014). The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail 36:1486–91.
   PubMed Web of Science ®Google Scholar
• Hayes-Jordan A, Green H, Ludwig J, Anderson P. (2012). Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis: early experience and phase 1 results. Pediatr Blood Cancer 59:395–7.
   PubMed Web of Science ®Google Scholar
• Green H. (2014 Jun). Perioperative renal protective treatment avoids renal toxicity in pediatric and adult patients undergoing HIPEC with cisplatin. J Pediatr Oncol 2:10–16.
   Google Scholar
• Bouhadjari N, Gabato W, Calabrese D, et al. (2016). Hyperthermic intraperitoneal chemotherapy with cisplatin: amifostine prevents acute severe renal impairment. Eur J Surg Oncol 42:219–23.
   PubMed Web of Science ®Google Scholar
• Lambert LA, Armstrong TS, Lee JJ, et al. (2009). Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol 16:2181–7.
   PubMed Web of Science ®Google Scholar
• Sin E, Chia C, Tan G, et al. (2017). Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia 33:690--95.
   PubMed Web of Science ®Google Scholar